**DRUG NAME:** Cytarabine

**SYNONYM(S):** 1-B-arabinofuranosylcytosine,\(^1\) arabinosylcytosine,\(^1\) ara-C,\(^1\) cytosine arabinoside\(^1\)

**COMMON TRADE NAME(S):** CYTOSAR®

**CLASSIFICATION:** antimetabolite\(^1\)

*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.*

**MECHANISM OF ACTION:**

Cytarabine, a synthetic pyrimidine nucleoside, is converted intracellularly, primarily by deoxycytidine kinase, to active cytarabine triphosphate.\(^1\)\(^,\)\(^,\)\(^2\) Activity occurs primarily as the result of inhibition of DNA polymerase via competition with deoxycytidine triphosphate, resulting in the inhibition of DNA synthesis.\(^2\) Incorporation of cytarabine into DNA and RNA may contribute to cytotoxic effects.\(^2\) Cytarabine also has antiviral and immunosuppressive properties.\(^2\)\(^,\)\(^4\) Cytarabine is cell cycle phase-specific for the S-phase; cytarabine may also block progression from the G1-phase to the S-phase.\(^2\) Both concentration and duration of exposure are critical for cytotoxicity.\(^5\)

**PHARMACOKINETICS:**

<table>
<thead>
<tr>
<th>Oral Absorption</th>
<th>(&lt;20%); ineffective when administered orally(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distribution</td>
<td>wide and rapid distribution into tissues and fluids(^1)(^,)(^2); crosses the placenta SC or IM: peak levels in 20-60 min, considerably lower peak levels than those obtained after IV(^1) IT: most of dose diffuses into systemic circulation, but is rapidly metabolized</td>
</tr>
<tr>
<td>cross blood brain barrier?</td>
<td>limited; CIVI or SC: CSF concentration (&lt; 60%) that of plasma, less after rapid IV(^6)</td>
</tr>
<tr>
<td>volume of distribution</td>
<td>2.6 L/kg</td>
</tr>
<tr>
<td>plasma protein binding</td>
<td>13%</td>
</tr>
<tr>
<td>Metabolism</td>
<td>rapid and extensive; primarily hepatic; also metabolized in the kidneys, GI mucosa, granulocytes, and other tissues by cytidine deaminase(^1); minimal metabolism in CSF(^3)(^,)(^6)</td>
</tr>
<tr>
<td>active metabolite</td>
<td>cytarabine triphosphate</td>
</tr>
<tr>
<td>inactive metabolite</td>
<td>uracil arabinoside</td>
</tr>
<tr>
<td>Excretion</td>
<td>urine 70-80%; 90% as uracil arabinoside, 10% unchanged</td>
</tr>
<tr>
<td>feces</td>
<td>no information found</td>
</tr>
<tr>
<td>terminal half life</td>
<td>1-3 h; variable(^4) IT: 2-4 h in CSF(^5)</td>
</tr>
<tr>
<td>clearance</td>
<td>IT: 0.42 mL/min(^8)</td>
</tr>
</tbody>
</table>

Adapted from standard reference\(^2\) unless specified otherwise.

**USES:**

**Primary uses:**  
*Leukemia, acute lymphocytic*  
*Leukemia, acute myeloid*  
*Leukemia, chronic myelogenous*  
*Leukemia, meningeal and other meningeal neoplasms (intrathecal)*  
*Lymphoma, non-Hodgkin’s; childhood*

**Other uses:**  
*Lymphoma, Hodgkin’s\(^2\)\(^,\)\(^4\)\(^,\)\(^6\)*  
*Lymphoma, non-Hodgkin’s; adult\(^1\)\(^,\)\(^3\)\(^,\)\(^4\)\(^,\)\(^6\)*  
*Myelodysplastic syndrome\(^4\)*

*Health Canada approved indication*
SPECIAL PRECAUTIONS:

**Caution:**
- Use cytarabine with caution in patients with pre-existing drug-induced bone marrow suppression or impaired hepatic function.²
- Because of potential toxicity, do not use products containing benzyl alcohol or products reconstituted with preserved diluent intrathecally, for neonates, or for high-dose cytarabine regimens.²
- High-dose therapy (2,000-3,000 mg/m²) may cause severe and sometimes fatal CNS, GI, and pulmonary toxicities.²

**Carcinogenicity:** Cytarabine is potentially carcinogenic.¹

**Mutagenicity:** Mutagenic in Ames test and mammalian in vitro mutation test. Cytarabine is clastogenic in mammalian in vitro and in vivo chromosome tests.³

**Fertility:** Both reversible and irreversible germ cell toxicity has been reported with cytarabine.⁴,¹⁰ The total dose below which there is no risk to fertility has not been established. Prediction of the degree of testicular or ovarian function impairment is complicated by several variables, including the route of administration, dose and length of therapy, frequency of treatment, and the use of combination therapy.⁴,¹⁰

**Pregnancy:** FDA Pregnancy Category D.⁴ There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

**Breastfeeding** is not recommended due to the potential secretion into breast milk.²

SIDE EFFECTS:
The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.¹¹ When placebo-controlled trials are available, adverse events are included if the incidence is >5% higher in the treatment group.

**High-dose is defined as 2,000-3,000 mg/m².**

<table>
<thead>
<tr>
<th>ORGAN SITE</th>
<th>SIDE EFFECT</th>
</tr>
</thead>
<tbody>
<tr>
<td>allergy/immunology</td>
<td>anaphylaxis with acute cardiopulmonary arrest (&lt;1%)</td>
</tr>
<tr>
<td></td>
<td>cutaneous small vessel necrotizing vasculitis³,⁸; with high-dose³</td>
</tr>
<tr>
<td>blood/bone marrow/febrile neutropenia</td>
<td>anemia; megaloblastic anemia (&lt;2%)⁴</td>
</tr>
<tr>
<td></td>
<td>*leukopenia (&gt;15%);⁴ *neutropenia; *onset within 24 hours, *1st nadir at 7-9 days with a brief recovery day 12, <em>2nd nadir greater than the first, at 15-24 days, recovery in the following 10 days</em></td>
</tr>
<tr>
<td></td>
<td><em>thrombocytopenia (&gt;15%);</em> onset 5 days, nadir 12-15 days, recovery in the following 10 days*</td>
</tr>
<tr>
<td>cardiovascular (general)</td>
<td>cardiomyopathy, cardiomegaly¹²</td>
</tr>
<tr>
<td></td>
<td>pericarditis with tamponade (&lt;0.1%); increased incidence with high-dose⁶; onset typically days after initiating treatment⁶</td>
</tr>
<tr>
<td>constitutional symptoms</td>
<td>fever (&gt;80%);¹²; unrelated to infection</td>
</tr>
<tr>
<td></td>
<td>weight gain; transient, secondary to severe intestinal toxicity</td>
</tr>
<tr>
<td>ORGAN SITE</td>
<td>SIDE EFFECT</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
</tr>
</tbody>
</table>
| dermatology/skin | *extravasation hazard: none*<sup>13</sup>  
alopecia (<10%); more frequent and complete with high-dose  
freckling (<10%)<sup>4</sup>  
injection site reactions; pain and inflammation (<2%);<sup>4,14</sup> thrombophlebitis, or cellulitis  
pruritis (<10%)<sup>4</sup>  
**rash (severe <1%); particularly affecting palms and soles of the feet,<sup>15,16</sup> increased incidence with high-dose**  
skin ulcerations |
| gastrointestinal | *emetogenic potential<sup>17</sup>; dose-related; high-moderate for > 1,000 mg/m<sup>2</sup>, low for 100-200 mg/m<sup>2</sup>*  
anorexia (≥15%)<sup>4</sup>  
**bowel necrosis, necrotizing colitis including oral and anal ulcerations, and pneumatoasis cystoides intestinalis leading to peritonitis; with high-dose**  
diarrhea (<10%)<sup>4</sup>  
esophagitis (<2%)<sup>4</sup>  
ileus  
mucositis (≥15%); severe with high-dose  
**nausea and vomiting (<2%); more frequent and severe with rapid IV administration of high-dose**  
protein-losing enteropathy |
| hemorrhage | hemorrhagic conjunctivitis; reversible<sup>4</sup>  
gastrointestinal hemorrhage (<2%)<sup>4</sup> |
| hepatobiliary/pancreas | hepatic dysfunction (<2%); increased incidence with high-dose  
pancreatitis |
| infection | infections, not otherwise specified; complicated by peritonitis, or liver abscesses; with high-dose  
intestinal infection  
**sepsis; with high-dose** |
| metabolic/laboratory | elevated amylase<sup>12</sup>  
elevated lipase<sup>12</sup>  
elevated transaminases and alkaline phosphatase  
hyperbilirubinemia  
hyperuricemia (<10%);<sup>4</sup>  
hypocalcemia  
hypokalemia |
| musculoskeletal | rhabdomyolysis; with high-dose<sup>6</sup> |
| neurology | dizziness (<10%);<sup>4</sup>  
**neurotoxicity (5-50%); increased incidence with high-dose**, see paragraph regarding high-dose therapy following Side Effects table |

Clinically important side effects are in **bold, italics**.
### ORGAN SITE | SIDE EFFECT
--- | ---
Clinically important side effects are in **bold, italics**

- **seizures (<1%); with IT**
- **somnolence; increased incidence with high-dose**

**ocular/visual**

- **ocular toxicity**, see paragraph regarding high-dose therapy following **Side Effects** table

**pain**

- pain including: abdominal pain, bone pain, chest pain, myalgia, and sore throat

**pulmonary**

- pulmonary toxicity (<2%); with relatively high-dose (e.g., >1,000 mg/m²), see paragraph regarding high-dose therapy following **Side Effects** table

**renal/genitourinary**

- renal dysfunction
- urinary retention (<2%)<sup>4</sup>

**sexual/reproductive function**

- germ cell toxicity; reversible and irreversible<sup>4</sup>

**syndromes**

- cytarabine syndrome (<2%); see paragraph following **Side Effects** table
- syndrome of sudden respiratory distress (<16%); see paragraph regarding high-dose therapy following **Side Effects** table

**vascular**

- veno-occlusive disease<sup>12</sup>

---

**Adapted from standard reference**<sup>2</sup> unless specified otherwise.

**Cytarabine syndrome**, a flu-like syndrome, characterized by fever, myalgia, bone pain, maculopapular rash, conjunctivitis, malaise, and occasionally chest pain, may begin 6-12 h after IV cytarabine.<sup>2</sup> This syndrome occurs more commonly after large doses; however, it can occur with small doses,<sup>6</sup> and has occurred after initial or subsequent courses of therapy.<sup>19,20</sup> A hypersensitivity mechanism may be responsible.<sup>6,19</sup> Symptoms usually resolve within 24 hours when cytarabine is discontinued; corticosteroids may be used for treatment and prophylaxis.<sup>1,2,19</sup> Cytarabine therapy may be continued with corticosteroid prophylaxis.<sup>1,2,19</sup>

**Administration:** Higher total doses are generally better tolerated when given by rapid IV injection compared to continuous IV infusion;<sup>1,3</sup> however, GI effects may be more pronounced with rapid IV injection.<sup>4,12</sup> The rate of administration does not affect the incidence of hematological toxicities.<sup>1,3</sup> This difference in tolerability may be due to the rapid clearance of cytarabine.<sup>2</sup>

**High-dose therapy** (2,000-3,000 mg/m²) has been associated with severe and potentially fatal toxicities which differ from those seen with usual low doses.

- **Ocular toxicities** may include vision loss, reversible corneal toxicity (keratitis), and hemorrhagic conjunctivitis (<80%).<sup>2,3,6</sup> Ocular toxicities have been reported 1-2 weeks after initiating therapy.<sup>6</sup> Symptoms may include tearing, eye pain, foreign body sensation, photophobia, and blurred vision.<sup>6</sup> Conjunctivitis may occur with rash. Toxicity can be minimized by prophylactic use of ophthalmic corticosteroids.<sup>6</sup> Use prednisolone 0.12% - 1% or dexamethasone 0.1%,<sup>12,21</sup> 2 drops in each eye every 4 hours, beginning before the first dose of cytarabine and continuing until 48 hours after the last one.<sup>21</sup> NS may also help relieve symptoms.<sup>12</sup>

- **Neurotoxicity** (8-10%) typically occurs 3-8 days after initiating therapy.<sup>2,4,12,22</sup> Cerebellar dysfunction is characterized by difficulty with speech, trouble standing or walking, and tremors. Cerebral dysfunction may be seen concomitantly and is characterized by somnolence, confusion, personality changes, cognitive dysfunction, memory loss, psychosis, or seizures. Seizures are usually self-limited. In most patients, neurologic dysfunction resolves in 5-10 days. There is a high incidence (~60%) of recurrent cerebellar toxicity in patients who have already experienced toxicity. It is not conclusively known if cytarabine therapy should be discontinued if neurological toxicity develops.<sup>23</sup>
Risk factors for developing cerebellar toxicity include: age over 50 years, impaired renal function (CrCl <60 mL/min), and total dose received. Prior CNS disease may also be risk factors. Methods used to decrease the risk of neurotoxicity in these patients include: decreasing the dose, utilizing a once-daily rather than twice-daily schedule, shortening the course of treatment, and modifying the dose based on the CrCl.

Peripheral motor and sensory neuropathies involving both upper and lower extremities have occurred. Neuropathies may manifest as muscle weakness, gait disturbances, paresthesias, myalgia, hypoalgesia, and hypoaesthesia. Dose adjustments may be required to avoid irreversible complications.

- Gastrointestinal toxicities may include GI ulceration, bowel necrosis, and necrotizing colitis including pneumatosis cystoides intestinalis leading to peritonitis. GI effects may be more pronounced with rapid IV injection compared to continuous IV infusion.
- Pulmonary toxicities may include interstitial pneumonitis, noncardiogenic pulmonary edema, and a potentially fatal syndrome of sudden respiratory distress (SRD) that includes cough, dyspnea, fever, tachypnea, hypoxemia, pneumonia, and interstitial and alveolar infiltrates progressing to pulmonary edema and cardiomyopathy. Pulmonary edema typically occurs 1-2 weeks after therapy, often after the first course. Pulmonary toxicities may correlate with the gastrointestinal lesions seen with cytarabine. Capillary leak syndrome may also be a factor in the development of SRD. Continuous infusions may be more likely than intermittent infusions to cause SRD. Treatment measures include supportive care, high-dose corticosteroids, and discontinuing cytarabine.
- Pancreatitis and hepatic injury.
- Palmar-plantar erythrodysesthesia, leading to desquamation, may occur with intermediate or high-dose therapy. Prophylactic topical steroids and/or skin moisturizers may be used.
- Fatal cardiomyopathy.

Tumour lysis syndrome: may result from cell lysis by cytotoxic chemotherapy and may lead to electrolyte disturbances or acute renal failure. It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients:
- aggressive hydration: 3 L/m²/24 hr with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required
- allopurinol 600 mg po initially, then 300 mg po q6h x 6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH>7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalization of the urine. It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminium hydroxide (e.g., AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminium hydroxide has been added, discontinue sodium bicarbonate.

Intrathecal administration: Side effects from intrathecal cytarabine administration are generally mild and self-limiting. Rarely, severe systemic toxicities have been reported. The most frequent of these are nausea, vomiting, and fever. Transient headaches may occur in up to 10% of patients. Intrathecal use of cytarabine has rarely been associated with neurotoxicities including meningitis, paresthesia, paraplegia, spastic paraparesis, and seizures. Blindness and necrotizing leukoencephalopathy have also been reported in patients receiving cytarabine in combination with other chemotherapeutic agents and/or radiation. Cytarabine neurotoxicity has been linked to diluents containing preservatives; use preservative-free diluents when preparing cytarabine for intrathecal use. Administering cytarabine IT and IV within a few days of each other may increase the risk of neurotoxicity.
**Sustained-release formulation for intrathecal administration:** A suspension of cytarabine encapsulated within a multivesicular lipid-based particle (DEPOCYT® 10 mg/mL), is available for intrathecal use. This sustained-release formulation of cytarabine has a half life in the CSF of 100-263 hours. Patients receiving liposomal cytarabine should receive dexamethasone 4 mg bid IV or PO for 5 days starting on day 1 to decrease the incidence of chemical arachnoiditis. Chemical arachnoiditis typically manifests as back pain, neck stiffness or pain, nausea and vomiting, headache, and fever. Adverse effects associated with liposomal cytarabine typically occur within 5 days of administration. The recommended dosage regimen for liposomal cytarabine is as follows:

- **Induction therapy:** 50 mg intrathecally every 14 days for 2 doses (weeks 1 and 3).
- **Consolidation therapy:** 50 mg intrathecally every 14 days for 3 doses (weeks 5, 7 and 9) followed by 1 additional dose at week 13.
- **Maintenance:** 50 mg intrathecally every 28 days for 4 doses (weeks 17, 21, 25 and 29).
- If drug-related neurotoxicity develops, reduce the dose to 25 mg. If toxicity persists, discontinue treatment.

**INTERACTIONS:**

<table>
<thead>
<tr>
<th>AGENT</th>
<th>EFFECT</th>
<th>MECHANISM</th>
<th>MANAGEMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>ciprofloxacin&lt;sup&gt;30&lt;/sup&gt;</td>
<td>decreased effect of ciprofloxacin</td>
<td>cytarabine-induced changes to intestinal mucosa cause a decrease in absorption of ciprofloxacin</td>
<td>monitor for response to ciprofloxacin, adjust ciprofloxacin dose as needed</td>
</tr>
<tr>
<td>digoxin&lt;sup&gt;1,2,30&lt;/sup&gt;</td>
<td>decreased effect of digoxin tablets</td>
<td>cytarabine-induced changes to intestinal mucosa cause a decrease in absorption of digoxin tablets</td>
<td>consider monitoring digoxin levels, adjust digoxin dose as needed</td>
</tr>
<tr>
<td>fludarabine&lt;sup&gt;3,31,32&lt;/sup&gt;</td>
<td>fludarabine given first appears to increase the therapeutic effects of cytarabine, cytarabine given first appears to inhibit the antineoplastic effect of fludarabine</td>
<td>fivefold increase in intracellular cytarabine concentrations in leukemic cells when fludarabine is given first, likely due to competition for deoxycytidine kinase, needed to convert both drugs to their active triphosphate</td>
<td>clinical importance as yet unknown</td>
</tr>
</tbody>
</table>

Theoretical: decreased *in vitro* effect of gentamycin against *Klebsiella pneumoniae* via antagonism of gentamycin activity by cytarabine. In the treatment of infections caused by *Klebsiella pneumoniae*, monitor for response to gentamycin. If a response is not achieved, consider alternate antibiotic therapy.<sup>2,30</sup>

**SUPPLY AND STORAGE:**

*Injection:*
Pfizer Canada Inc supplies cytarabine as a sterile solution for injection without preservative in 100 mg (5 mL) and 500 mg (25 mL) single use vials at a concentration of 20 mg/mL and in 1000 mg (10 mL) and 2000 mg (20 mL) single use vials at a concentration of 100 mg/mL. Store at room temperature. Protect from light.<sup>33</sup>

Hospira Healthcare Corporation supplies cytarabine as a sterile solution without preservative in single use vials of 100 mg (1mL), 500 mg (5mL), 1000 mg (10 mL), and 2000 mg (20 mL) at a concentration of 100 mg/mL. Store at room temperature. Protect from light.<sup>34</sup>

*For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.*
SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see Chemotherapy Preparation and Stability Chart in Appendix.

Compatibility: consult detailed reference

PARENTERAL ADMINISTRATION:

<table>
<thead>
<tr>
<th>Method</th>
<th>BCCA administration guideline noted in bold, italics</th>
</tr>
</thead>
</table>
| Subcutaneous                | has been used; continuous SC infusions have also been used
| Intramuscular               | has been used
| Direct intravenous          | has been used
| *Intermittent infusion      | over 15 min for doses <1,000 mg/m²; over 1-3 h for high-dose
| *Continuous infusion        | has been used
| Intrapertoneal              | no information found
| Intrapleural                | no information found
| †Intrathecal                | qs to 6 mL with preservative-free NS
|                             | alternatively may be diluted in 5-15 mL of solution to achieve a concentration of 5 mg/mL
|                             | children: dilute in 5-15 mL of solution to achieve a concentration of 5 mg/mL
|                             | liposomal cytarabine: over 1-5 min
| Intra-arterial              | no information found
| Intravesical                | no information found

*High-dose cytarabine requires preservative-free diluent.²
†Intrathecal cytarabine requires preservative-free cytarabine and diluent. See BC Cancer Agency Policy III-50 Administration of Cytotoxic Drugs by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir in Appendix.

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:

<table>
<thead>
<tr>
<th>Method</th>
<th>BCCA usual dose noted in bold, italics</th>
</tr>
</thead>
</table>
| Intravenous     | Cycle Length: 2 weeks¹,²,³,⁴: 200 mg/m² IV over 24 hours for 5 consecutive days starting on day 1 (total dose per cycle 1000 mg/m²)
|                 | 2-4 weeks¹,²,³,⁴: 100 mg/m² (range 100-200 mg/m²) IV over 24 hours (or divided in 2 or 3 doses) for 7 consecutive days (range 5-10 days) starting on day 1 (total dose per cycle 700 mg/m² [range 500-2,000 mg/m²])
Cycle Length:

**High-dose therapy**\(^2,6,12,23\): 3,000 mg/m\(^2\) (range 1,000-3,000 mg/m\(^2\)) IV every 12 hours for 2-6 consecutive days starting on day 1 (total dose range 4,000-36,000 mg/m\(^2\))

**note**: high-dose therapy should only be used by physicians experienced in managing its side effects

**Subcutaneous:**

**4-6 weeks**\(^38,39\): 20 mg SC twice daily for 10 consecutive days (total dose per cycle 400 mg)

1-4 weeks\(^2\): 1 mg/kg (range 1-1.5 mg/kg) SC for one dose on day 1 (total dose per cycle 1 mg/kg [range 1-1.5 mg/kg])

4 weeks\(^40\): 20 mg/m\(^2\) SC once daily for 10 consecutive days (total dose per cycle 200 mg/m\(^2\))

n/a\(^2\): 10-20 mg SC daily (or divided) for 21-42 consecutive days (total dose 210-840 mg)

**Intrathecal:**

**1 week**\(^35,36\): 50 mg IT for one dose once weekly (range once or twice weekly) (maximum two IT injections per week) (total dose per cycle 50 mg/m\(^2\) [range 50-100 mg/m\(^2\)])

n/a\(^2\): 30 mg/m\(^2\) (range 5-75 mg/m\(^2\)) IT for one dose every 4 days (range 2-7 days) until CSF findings normalize, typically followed by one additional dose

n/a\(^37\): 50 mg IT for one dose on day 1 (total dose per cycle 50 mg/m\(^2\))

**Concurrent radiation:**

irradiation erythema has been reported in patients who have received radiation\(^16\)

**Concurrent chemotherapy:**

adjustment of concurrent systemic chemotherapy may be required when administering intrathecal cytarabine\(^5\)

**Dosage in myelosuppression:**

modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"

**Dosage in renal failure:**

no adjustment required\(^2,7\); for **high-dose therapy** the following dose-modification algorithm may be used to minimize neurotoxicity\(^6\); the risk of neurotoxicity with high-dose cytarabine is directly related to renal function throughout therapy,\(^9\) see paragraph following **Side Effects** table

<table>
<thead>
<tr>
<th>Creatinine clearance (mL/min)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;60</td>
<td>100%</td>
</tr>
<tr>
<td>46-60</td>
<td>60%</td>
</tr>
<tr>
<td>31-45</td>
<td>50%</td>
</tr>
<tr>
<td>&lt; 30</td>
<td>discontinue, consider alternate therapy</td>
</tr>
</tbody>
</table>

Calculated creatinine clearance = \(N^* \times (140 - \text{Age}) \times \text{weight (kg)}\) \(\text{Serum Creatinine in } \mu\text{mol/L}\)

* For males \(N = 1.23\); for females \(N = 1.04\)
BCCA usual dose noted in **bold, italics**

**Dosage in hepatic failure:**
- Cycle Length:
- Dosage in hepatic failure:
  - dose reduction may not be necessary\(^1,2\); if adjusted the following guideline has been used\(^12\):
    - a 50% initial dose reduction if bilirubin \(\geq 34\) umol/L and increase as tolerated

**Dosage in dialysis:**
- hemodialysis: supplemental dose is not necessary\(^12\)
- continuous ambulatory peritoneal dialysis (CAPD): supplemental dose is not necessary\(^12\)
- continuous arteriovenous hemofiltration (CAVH): adjustment not required\(^7\)

**Children:**
- Cycle Length:
- Intravenous:
  - 2-4 weeks\(^{41,42}\):
    - 200 mg/m\(^2\) (range 70-200 mg/m\(^2\)) IV over 24 hours or divided IV every 12 hours for 5 consecutive days (range 2-10 days) starting on day 1
    - (total dose per cycle 1,000 mg/m\(^2\) [range 140-2,000 mg/m\(^2\)])
  - *High-dose therapy*\(^{41,42}\):
    - 3,000 mg/m\(^2\) IV every 12 hours for up to 6 consecutive days starting on day 1
    - (total dose \(<36,000\) mg/m\(^2\))
    - **note:** high-dose therapy should only be used by physicians experienced in managing its side effects

- Subcutaneous/Intramuscular:
  - 1-4 weeks\(^{41}\):
    - 1 mg/kg (range 1-1.5 mg/kg) SC or IM for one dose on day 1
    - (total dose per cycle 1 mg/kg [range 1-1.5 mg/kg])

- Intrathecal:
  - n/a\(^6,41\):
    - 30 mg/m\(^2\) (range 5-75 mg/m\(^2\)) IT for one dose every 4 days (range 2-7 days) until CSF findings normalize, followed by one additional dose

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>20 mg</td>
</tr>
<tr>
<td>1-2</td>
<td>30 mg</td>
</tr>
<tr>
<td>2-3</td>
<td>50 mg</td>
</tr>
<tr>
<td>&gt;3</td>
<td>70 mg</td>
</tr>
</tbody>
</table>

The safety and effectiveness of liposomal cytarabine in children has not been established.\(^9\)

*do not use diluents containing benzyl alcohol in neonates*\(^2\)

**REFERENCES:**
